Drugs and patents in ATC class N05AA - Phenothiazines with aliphatic side-chain

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
THORAZINE	chlorpromazine
THORAZINE	chlorpromazine hydrochloride
CHLORPROMAZINE HYDROCHLORIDE	chlorpromazine hydrochloride
CHLORPROMAZINE HYDROCHLORIDE INTENSOL	chlorpromazine hydrochloride
SONAZINE	chlorpromazine hydrochloride
>Tradename	>Generic Name

Last updated: June 12, 2026

What is the market size and growth outlook for ATC N05AA phenothiazines with aliphatic side-chain?

ATC N05AA covers first-generation antipsychotics in the phenothiazine series with an aliphatic side chain. In practice, the commercial base is dominated by older, largely off-patent molecules (especially chlorpromazine) and closely related legacy phenothiazines used across schizophrenia, bipolar-related psychosis, and off-label indications such as nausea, agitation, and hiccups. Demand dynamics are shaped by:

Generic penetration: Most N05AA products face early genericization in most major markets, leaving limited room for new entrant IP value.
Formulation churn: Sustained commercial activity is driven by incremental differentiation in oral solid dosage (tabs), oral liquid (where used), and depot injectables where applicable.
Guideline positioning: These drugs remain relevant where cost and availability matter, despite long-standing preference shifts toward second-generation antipsychotics.
Safety-driven switching: Extrapyramidal symptom risk and tardive dyskinesia concerns affect switching patterns, but they do not eliminate use in lower-acuity or cost-sensitive settings.

Commercial implication: For most incumbents in N05AA, growth is not “patent-led.” It is volume-led (hospital formularies, generics uptake dynamics, payer contracting) and brand-led (controlled switching and pharmacovigilance familiarity where brand retention exists).

Which phenothiazines belong to ATC N05AA and what products drive revenue?

ATC N05AA is a chemical-class bucket: “phenothiazines with aliphatic side-chain.” The most economically material active ingredient historically is chlorpromazine. Other phenothiazines in the same mechanistic family often appear in overlapping classification contexts (and can be adjacent in ATC structure), but the commercial center of gravity for N05AA-like use patterns is typically chlorpromazine and its regional brand/depot variants.

Key market drivers by molecule (high-level):

Chlorpromazine: Sustained use for psychosis and off-label antiemetic and preoperative sedation in some regions. Depot formulations exist in multiple geographies historically, driving longer inventory cycles even after patent expiration.
Other aliphatic-side-chain phenothiazines: Smaller, more regionally concentrated revenue pools; often dominated by generics and supply stability rather than IP exclusivity.

What is the patent estate status for N05AA phenothiazines in the US, EU, and key generics markets?

Executive answer: The patent estate for N05AA phenothiazines is mostly mature and largely exhausted at the active-ingredient level. The remaining enforceable value tends to shift to:

Formulation patents (controlled-release, depot manufacturing, specific salts/hydrates, particle size control).
Method-of-use patents (narrow dosing regimens or new indications).
Device-adjacent IP (delivery systems for injectables, though this is more common in newer platforms than in first-generation phenothiazines).
Secondary process IP (manufacturing and sterilization improvements for injectables, scale-up, or impurity profiles).

Practical consequence for entry strategy: For a generic or biosimilar-adjacent strategy, the dominant risk is not the old base compound. It is secondary IP that may still be live around specific dosage forms or manufacturing processes.

Which patents protect chlorpromazine and other N05AA phenothiazines in major jurisdictions?

Executive answer: Without an exact, molecule-level list of marketed N05AA products by country and their corresponding Orange Book / EMA listing entries, a defensible, patent-number-level mapping cannot be produced here without risking factual inaccuracy.

When do N05AA phenothiazines lose exclusivity and how much is left by dosage form?

Executive answer: Base-compound exclusivity for first-generation phenothiazines is generally long expired. Any remaining exclusivity typically comes from:

Patent life extension and secondary patents around specific formulations,
Regulatory data exclusivity tied to reformulated products in rare cases,
Patent thickets around injectable depots and manufacturing.

Market impact by dosage form

Oral tablets and liquids: Lowest residual exclusivity risk because generic versions are common and formulation differentiation tends to be easy to replicate after initial innovations.
Injectables (including depot forms where marketed): Higher residual thicket risk because manufacturing controls and impurity profiles can be patent-protected and difficult to design around quickly.
Niche strengths/brands: Residual exclusivity can persist if a single supplier owns a later-generation formulation or combination product.

What patent litigation affects generic entry for N05AA phenothiazines?

Executive answer: N05AA litigation is typically intermittent and often centers on:

Paragraph IV challenges to patents listed for specific branded presentations (often oral solids or depot injectable forms),
Infringement disputes on formulation and process claims.

A litigation-focused analysis requires a product-to-patent mapping tied to a specific brand presentation (US ANDA caselists, EU opposition records, and/or national court filings). Without those identifiers, listing exact cases and dates would be speculative.

What is the Orange Book status of ATC N05AA phenothiazines with aliphatic side-chain?

Executive answer: Orange Book status is presentation-specific. For N05AA, the active-ingredient-level exclusivity is usually expired, but specific listed patents may persist for:

Method-of-use,
Formulation/controlled release,
Packaging or manufacturing.

A correct Orange Book table must include: NDA/ANDA reference listed drug, ANDA number, active ingredient, dosage form, applicant, patent numbers, listed expiration dates, and whether patents are withdrawn/expired. That requires product-level input that is not provided here.

How strong is the patent estate for N05AA phenothiazines: formulation vs method-of-use?

Executive answer: For first-generation phenothiazines, the highest remaining enforceability typically lies in formulation and manufacturing rather than broad compound claims. Method-of-use claims, when they exist, are often narrower and can be designed around through:

Different dosing schedules,
Different patient cohorts,
Different labeled indication scope.

Entry risk framing

Low risk: Pure generic oral versions where no live formulation/process patents are listed for that presentation.
Medium risk: Reformulated generics (e.g., depot or controlled-release) that could intersect with formulation claims.
High risk: Injectables with active manufacturing/process constraints, where design-around may require extended stability and impurity qualification.

What generic entry risks exist for N05AA phenothiazines by route of administration?

Executive answer: Route is the risk discriminator.

Oral: Usually lower IP friction due to longstanding generic supply chains and easier generic bioequivalence.
Depot/injectable: Higher risk from residual formulation/process IP, and from potential FDA-specific suitability constraints tied to manufacturing controls.

Design-around common patterns

Switch to a different release mechanism (where applicable),
Change excipient system to avoid specific formulation claim elements,
Modify manufacturing steps to avoid process claim infringement,
Use different particle size distributions or sterilization/impurity control methods.

How do N05AA phenothiazines compare with other antipsychotic classes in patent and market dynamics?

Executive answer: In antipsychotics, N05AA phenothiazines behave like classic off-patent small molecules:

Patents are not the primary growth lever in most regions.
Market dynamics are competitive and payer-driven: generic price compression is the default endpoint.
Innovation is mainly incremental: depot improvements, controlled release, or packaging/manufacturing refinements rather than new mechanism discovery.

Compared with newer antipsychotics (especially second-generation and long-acting injectables), N05AA lacks sustained, mechanism-based patent tailwinds.

Are there biologic or biosimilar risks in ATC N05AA?

Executive answer: No. N05AA is a small-molecule class of phenothiazines. Biosimilar frameworks do not apply.

What company strategies matter most in N05AA: incumbents vs generics vs supply-chain?

Executive answer: Competitive advantage in N05AA is typically supply-chain execution and contract positioning, not patent exclusivity. Strategies that matter:

Line clearance and manufacturing redundancy for sterile injectables (where relevant),
Portfolio breadth across strengths and dosage forms to win formulary coverage,
Speed-to-market when listed secondary patents expire,
Defensive brand lifecycle management where a regional brand retains market share via contracts.

Key takeaways

ATC N05AA phenothiazines with aliphatic side-chains are dominated by legacy, small-molecule antipsychotics, with limited remaining active-ingredient exclusivity.
The residual patent landscape, where it exists, is mostly secondary IP: formulation, manufacturing, and sometimes narrow method-of-use claims.
Market dynamics are generic- and supply-driven. Route of administration is the main differentiator for IP and entry risk, with injectables/depot forms carrying higher residual thicket potential.
A litigation and Orange Book mapping is presentation-specific; without listing the exact branded/generic products, product-to-patent tables would be inaccurate.

FAQs

Which N05AA products typically retain live patents the longest, oral vs depot?
How do formulation patents for phenothiazines differ from compound patents in generic design-around?
What FDA pathway is usually used for generic phenothiazine antipsychotics and how does it interact with listed patents?
Do method-of-use claims for older antipsychotics materially delay generic launch?
What supply-chain factors most often disrupt availability of older injectable antipsychotics in the US and EU?

References

European Medicines Agency (EMA). ATC classification and antipsychotic therapeutic area materials.
FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search portal and methodology).
WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index.

Drugs in ATC Class N05AA

Drugs in ATC Class: N05AA - Phenothiazines with aliphatic side-chain

Market dynamics and patent landscape for ATC Class N05AA (Phenothiazines with aliphatic side-chain)